Bicycle Therapeutics implemented structured workforce reductions, cutting approximately 30 percent of its personnel across its United Kingdom and United States operations. These difficult organizational cutbacks were initiated to dramatically lower ongoing corporate overhead expenses, streamline research and development spending following pipeline adjustments, and successfully preserve capital reserves to fund critical clinical trial readouts for its core oncology pipeline without requiring immediate dilutive financing.